Camrelizumab plus concurrent chemoradiotherapy for locally advanced cervical cancer: Preliminary results of a single-arm, open-label, phase II trial

被引：1
|
作者：
Xiao, Y. [1 ]
Cheng, H. [2 ,3 ]
Wang, L. [1 ]
Yang, L. [1 ]
Yu, X. [1 ]
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Gynaecol Oncol, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Affiliated Canc Hosp, Dept Gynaecol Oncol, Zhengzhou, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.690
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
562P
引用
收藏
页码：S805 / S805
页数：1
相关论文
共 50 条
  • [31] Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi
    Zhang, Wei-Jing
    You, Rui
    Zou, Xiong
    Wang, Zhi-Qiang
    Ouyang, Yan-Feng
    Peng, Lan
    Liu, You-Ping
    Duan, Chong-Yang
    Yang, Qi
    Lin, Chao
    Xie, Yu-Long
    Chen, Si-Yuan
    Liu, Yong-Long
    Gu, Chen-Mei
    Xie, Ruo-Qi
    Huang, Pei-Yu
    Hong, Ming-Huang
    Hua, Yi-Jun
    Chen, Ming-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2571 - +
  • [32] A prospective, single-arm, open-label study of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer
    Li, G.
    Zhao, Y.
    Jiang, Y.
    Yang, Q.
    Huang, A.
    Chen, Y.
    Han, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S753 - S754
  • [33] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [34] Nab-paclitaxel and cisplatin-based concurrent chemoradiotherapy for locally advanced cervical cancer: A prospective, single-arm phase II clinical trial
    Li, Mingyi
    Qin, Qinghua
    Zhang, Yiqian
    Wu, Qiuyan
    Li, Zhouyu
    Yang, Xinglong
    Cai, Zhantuo
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S72 - S72
  • [35] Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
    Ren, Shengxiang
    He, Jianxing
    Fang, Yong
    Chen, Gongyan
    Ma, Zhiyong
    Chen, Jianhua
    Guo, Renhua
    Lin, Xiaoyan
    Yao, Yu
    Wu, Gang
    Wang, Quanren
    Zhou, Caicun
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (05):
  • [36] Anlotinib in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase. trial.
    Wu, Xiaohua
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial
    Zhang, Xuyu
    Zhou, Feng
    Lu, Tong
    Zhang, Shun
    Wei, Xuedong
    Qiu, Xuefeng
    Xu, Linfeng
    Guo, Hongqian
    Zhuang, Junlong
    WORLD JOURNAL OF UROLOGY, 2025, 43 (01)
  • [38] Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
    Migden, Michael R.
    Khushalani, Nikhil I.
    Chang, Anne Lynn S.
    Lewis, Karl D.
    Schmults, Chrysalyne D.
    Hernandez-Aya, Leonel
    Meier, Friedegund
    Schadendorf, Dirk
    Guminski, Alexander
    Hauschild, Axel
    Wong, Deborah J.
    Daniels, Gregory A.
    Berking, Carola
    Jankovic, Vladimir
    Stankevich, Elizabeth
    Booth, Jocelyn
    Li, Siyu
    Weinreich, David M.
    Yancopoulos, George D.
    Lowy, Israel
    Fury, Matthew G.
    Rischin, Danny
    LANCET ONCOLOGY, 2020, 21 (02): : 294 - 305
  • [39] Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
    Chen, Li
    Jiang, Yi-Zhou
    Wu, Song-Yang
    Wu, Jiong
    Di, Gen -Hong
    Liu, Guang-Yu
    Yu, Ke-Da
    Fan, Lei
    Li, Jun-Jie
    Hou, Yi-Feng
    Hu, Zhen
    Chen, Can-Ming
    Huang, Xiao-Yan
    Cao, A-Yong
    Hu, Xin
    Zhao, Shen
    Ma, Xiao-Yan
    Xu, Ying
    Sun, Xiang-Jie
    Chai, Wen -Jun
    Guo, Xiaomao
    Chen, Xizi
    Xu, Yanhui
    Zhu, Xiao-Yu
    Zou, Jian-Jun
    Yang, Wen-Tao
    Wang, Zhong-Hua
    Shao, Zhi-Ming
    CLINICAL CANCER RESEARCH, 2022, 28 (13) : 2807 - 2817
  • [40] Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial
    Zhao, Yuzhou
    Li, Danyang
    Zhuang, Jing
    Li, Zhimeng
    Xia, Qingxin
    Li, Zhi
    Yu, Juan
    Wang, Jinbang
    Zhang, Yong
    Li, Ke
    Xu, Shuning
    Li, Sen
    Ma, Pengfei
    Cao, Yanghui
    Liu, Chenyu
    Xu, Chunmiao
    Liu, Zhentian
    Wei, Jinwang
    Zhang, Chengjuan
    Qiao, Lei
    Gao, Xuan
    Hou, Zhiguo
    Liu, Chenxuan
    Zheng, Rongrong
    Wang, Du
    Liu, Ying
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (05):
12345